[1]CurrentPatentAssignee:SICHUANKELUNPHARMACEUTICALCOMPANYLIMITED-CN106554354,2017,ALocationinpatent:Paragraph0134-0137
[2]CurrentPatentAssignee:LUNANPHARMACEUTICALGROUPCOLTD-CN111574520,2020,ALocationinpatent:Paragraph0173-0175
[3]CurrentPatentAssignee:LUNANPHARMACEUTICALGROUPCOLTD-CN111574463,2020,ALocationinpatent:Paragraph0177-0178
[4]CurrentPatentAssignee:ChifengSailintaiPharmaceuticalCo.,Ltd.;Cui,Yujie;Zhang,Lihua;Zhao,Hongwei;Wang,Yanfeng;Ji,Liping;Sheng,Li;Wang,Jieting;Ma,Zheng-2016Locationinpatent:Paragraph0053;0054;0055;0056
[5]CurrentPatentAssignee:CHIFENGSALIONTPHARMACEUTICAL-CN105936634,2016,ALocationinpatent:Paragraph0123;0124;0125;0126
[6]CurrentPatentAssignee:ChifengSailintaiPharmaceuticalCo.,Ltd.;Cui,Yujie;Zhang,Lihua;Zhao,Hongwei;Wang,Yanfeng;Ji,Liping;Sheng,Li;Wang,Jieting;Ma,Zheng-2016Locationinpatent:Paragraph0053;0054;0055;0056
[7]Eckhardt,Matthias;Langkopf,Elke;Mark,Michael;Tadayyon,Moh;Thomas,Leo;Nar,Herbert;Pfrengle,Waldemar;Guth,Brian;Lotz,Ralf;Sieger,Peter;Fuchs,Holger;Himmelsbach,Frank[JournalofMedicinalChemistry,2007,vol.50,#26,p.6450-6453]
[8]CurrentPatentAssignee:NANJINGJUNRUOBIOMEDICALRESINSTITUTE;HAIMENBAIKANGPHARMACEUTICAL;JIANGSUJUNRUOPHARMACEUTICAL-CN110872292,2020,ALocationinpatent:Paragraph0037-0038
[9]CurrentPatentAssignee:WEIHAIKAIMEIKEMEDICALTECHNOLOGYDEV-CN104844602,2018,BLocationinpatent:Paragraph0045;0046
[10]CurrentPatentAssignee:2YCHEM-US2015/274728,2015,A1Locationinpatent:Paragraph0224-0228
[11]CurrentPatentAssignee:SHANGHAIWONDERPHARMACEUTICALCOLTD-CN105622609,2016,ALocationinpatent:Paragraph0051
[12]CurrentPatentAssignee:SHANGHAIMODERNPHARMACEUTICALCO.,LTD.;CHINANATIONALPHARMACEUTICALGROUPCORPORATION-CN106478629,2017,ALocationinpatent:Paragraph0022-0027
[13]CurrentPatentAssignee:GANLEEPHARMACEUTICALSJIANGSU-CN110964013,2020,ALocationinpatent:Paragraph0033;0041-0043;0044-0065
[14]CurrentPatentAssignee:HEFEIYUANZHIPHARMACEUTICALRD-CN106008508,2016,ALocationinpatent:Paragraph0016;0023;0024;0025;0031;0032
[15]CurrentPatentAssignee:SUNPHARMACEUTICALINDUSTRIESLIMITED-WO2015/11609,2015,A1Locationinpatent:Page/Pagecolumn13
[16]CurrentPatentAssignee:YAMASACORPORATION-JP2020/70296,2020,ALocationinpatent:Paragraph0061-0067
[17]CurrentPatentAssignee:PERMIRAHOLDINGSLIMITED;CAMBREXPROFARMACOMILANOSRL-WO2019/219620,2019,A1Locationinpatent:Page/Pagecolumn12
[18]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-US2013/123282,2013,A1Locationinpatent:Paragraph0158
[19]CurrentPatentAssignee:ZYDUSLIFESCIENCESLTD-WO2013/171756,2013,A1Locationinpatent:Page/Pagecolumn17
[20]CurrentPatentAssignee:VIATRISINC-WO2014/97314,2014,A1Locationinpatent:Page/Pagecolumn11-12
[21]Lai,Zeng-Wei;Li,Chunhong;Liu,Jun;Kong,Lingyi;Wen,Xiaoan;Sun,Hongbin[EuropeanJournalofMedicinalChemistry,2014,vol.83,p.547-560]
[22]CurrentPatentAssignee:WOCKHARDTLIMITED-WO2015/4599,2015,A1Locationinpatent:Page/Pagecolumn19
[23]CurrentPatentAssignee:ZYDUSLIFESCIENCESLTD-US2015/51228,2015,A1Locationinpatent:Paragraph0141
[24]CurrentPatentAssignee:QILUPHARMACEUTICALGROUPCOLTD-CN105272982,2016,ALocationinpatent:Paragraph0044-0045
[25]CurrentPatentAssignee:BIOCONLIMITED-WO2019/64214,2019,A1Locationinpatent:Page/Pagecolumn10;11
[26]CurrentPatentAssignee:SHENZHENSECONDPEOPLE`SHOSPITAL-CN110590780,2019,ALocationinpatent:Paragraph0052-0056
[27]CurrentPatentAssignee:KYONGBOPHARM-KR2019/124536,2019,ALocationinpatent:Paragraph0048-0051
[28]CurrentPatentAssignee:BEIJINGRONGYINGPHARMACEUTICALTECH-CN110615790,2019,ALocationinpatent:Paragraph0004;0008;0009
[29]CurrentPatentAssignee:YANGTZERIVERPHARMACEUTICALGROUPCOLTD-CN110684026,2020,ALocationinpatent:Paragraph0040;0045-0047;0052-0054;0059;0061;0066-0067
[30]CurrentPatentAssignee:SHANDONGYONGCHENGPHARMACY-CN112724140,2021,ALocationinpatent:Paragraph0041;0048-0059
[31]Wang,Hailong;Chen,Kai;Lin,Biyue;Kou,Jingping;Li,Lijun;Wu,Shuming;Liao,Shouzhu;Sun,Guodong;Pu,Junwen;Yang,Hua;Wang,Zhongqing[OrganicProcessResearchandDevelopment,2022,vol.26,#12,p.3254-3264]
[1]CurrentPatentAssignee:WEIHAIKAIMEIKEMEDICALTECHNOLOGYDEV-CN104844602,2018,BLocationinpatent:Paragraph0050;0051
[2]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-WO2006/48427,2006,A1Locationinpatent:Page/Pagecolumn11-12
[3]CurrentPatentAssignee:2YCHEM-US2015/274728,2015,A1Locationinpatent:Paragraph0229-0235
[4]CurrentPatentAssignee:PERMIRAHOLDINGSLIMITED;CAMBREXPROFARMACOMILANOSRL-WO2019/219620,2019,A1Locationinpatent:Page/Pagecolumn12;13;14
[5]CurrentPatentAssignee:C.H.BoehringerSohnAG&Co.KG-WO2006/48427,2006,A1Locationinpatent:Page/Pagecolumn12
[1]CurrentPatentAssignee:DIPHARMAFRANCISS.R.L.-EP2468749,2012,A1Locationinpatent:Page/Pagecolumn8
[2]CurrentPatentAssignee:DIPHARMAFRANCISS.R.L.-US2012/165525,2012,A1Locationinpatent:Page/Pagecolumn5-6
[3]CurrentPatentAssignee:CHEMELECTIVA-WO2015/67539,2015,A1Locationinpatent:Page/Pagecolumn16;17
[1]CurrentPatentAssignee:DIPHARMAFRANCISS.R.L.-EP2468749,2012,A1Locationinpatent:Page/Pagecolumn9
[2]CurrentPatentAssignee:DIPHARMAFRANCISS.R.L.-US2012/165525,2012,A1Locationinpatent:Page/Pagecolumn6
[1]CurrentPatentAssignee:DIPHARMAFRANCISS.R.L.-EP2468749,2012,A1Locationinpatent:Page/Pagecolumn9
Title: Neuroprotective effect of linagliptin against cuprizone-induced demyelination and behavioural dysfunction in mice: A pivotal role of AMPK/SIRT1 and JAK2/STAT3/NF-κB signalling pathway modulation.
Journal: Toxicology and applied pharmacology 20180801
Title: The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndrome.
Journal: Chemico-biological interactions 20170801
Title: Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201
Title: [Oral antidiabetic drugs in chronic renal disease].
Journal: Orvosi hetilap 20121104
Title: Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine.
Journal: Diabetes, obesity & metabolism 20121101
Title: Recent advances in incretin-based therapies.
Journal: Clinical endocrinology 20121001
Title: Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Journal: Cardiovascular research 20121001
Title: Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Journal: Nature reviews. Endocrinology 20121001
Title: Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Journal: Bioorganic & medicinal chemistry 20121001
Title: Linagliptin as add-on therapy for type 2 diabetes - an overview.
Journal: Drugs of today (Barcelona, Spain : 1998) 20121001
Title: Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Journal: Drugs 20120910
Title: The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Journal: The Journal of endocrinology 20120901
Title: Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
Journal: Current molecular medicine 20120901
Title: Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Journal: Current medical research and opinion 20120901
Title: Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Journal: Clinical therapeutics 20120901
Title: [Use of oral glucose-lowering agents in patients with renal impairment].
Journal: Revue medicale suisse 20120829
Title: Gliptin versus a sulphonylurea as add-on to metformin.
Journal: Lancet (London, England) 20120804
Title: 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Journal: Lancet (London, England) 20120804
Title: The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Journal: Diabetes, obesity & metabolism 20120801
Title: GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
Journal: Current clinical pharmacology 20120801
Title: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Journal: Clinical pharmacokinetics 20120801
Title: Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Journal: British journal of clinical pharmacology 20120701
Title: The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
Journal: The Journal of pharmacology and experimental therapeutics 20120701
Title: The incretin hormones: from scientific discovery to practical therapeutics.
Journal: Diabetologia 20120701
Title: Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Journal: Clinical pharmacokinetics 20120701
Title: Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.
Journal: Expert opinion on pharmacotherapy 20120701
Title: Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946.
Journal: Diabetes, obesity & metabolism 20120701
Title: Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Journal: Postgraduate medicine 20120701
Title: Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Journal: Diabetes, obesity & metabolism 20120601
Title: Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.
Journal: Current drug targets 20120601
Title: Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
Journal: Diabetes, obesity & metabolism 20120501
Title: An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Journal: Current diabetes reviews 20120501
Title: Review of linagliptin for the treatment of type 2 diabetes mellitus.
Journal: Clinical therapeutics 20120501
Title: The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
Journal: International journal of clinical pharmacology and therapeutics 20120501
Title: Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411
Title: Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Journal: Diabetes, obesity & metabolism 20120401
Title: DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Journal: Diabetes & metabolism 20120401
Title: Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Journal: Diabetes technology & therapeutics 20120401
Title: Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Journal: Diabetes, obesity & metabolism 20120401
Title: [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120401
Title: New drugs 2012 part I.
Journal: Nursing 20120301
Title: Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Journal: The Annals of pharmacotherapy 20120301
Title: Pleiotropic effects of incretins.
Journal: Indian journal of endocrinology and metabolism 20120301
Title: Annual drug update: 2011 in review.
Journal: The Nurse practitioner 20120212
Title: [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Journal: Revue medicale de Liege 20120201
Title: Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Journal: Cardiology in review 20120101
Title: A review of gliptins in 2011.
Journal: Expert opinion on pharmacotherapy 20120101
Title: Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Journal: Expert opinion on pharmacotherapy 20120101
Title: DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Journal: Advances in therapy 20120101
Title: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Journal: Cardiovascular diabetology 20120101
Title: Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Journal: Cardiovascular diabetology 20120101
Title: Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.
Journal: Diabetology & metabolic syndrome 20120101
Title: Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Journal: BMC pharmacology 20120101
Title: Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
Journal: CANNT journal = Journal ACITN 20120101
Title: Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.
Journal: Experimental diabetes research 20120101
Title: Red carpeting the newer antidiabetics.
Journal: Journal of pharmacology & pharmacotherapeutics 20120101
Title: The management of type 2 diabetic patients with hypoglycaemic agents.
Journal: ISRN endocrinology 20120101
Title: Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Journal: Current medicinal chemistry 20120101
Title: Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.
Journal: PloS one 20120101
Title: Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
Journal: Clinical medicine insights. Endocrinology and diabetes 20120101
Title: Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
Title: Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.
Journal: Swiss medical weekly 20120101
Title: Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals.
Journal: Clinical laboratory 20120101
Title: Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.
Journal: Journal of nutrition and metabolism 20120101
Title: Impact of diabetes on postinfarction heart failure and left ventricular remodeling.
Journal: Current heart failure reports 20111201
Title: Linagliptin for the treatment of type 2 diabetes.
Journal: Expert opinion on pharmacotherapy 20111201
Title: Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Journal: Expert opinion on drug metabolism & toxicology 20111201
Title: Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.
Journal: P & T : a peer-reviewed journal for formulary management 20111201
Title: [Incretin-based therapy for treating patients with type 2 diabetes].
Journal: Orvosi hetilap 20111127
Title: Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Journal: Diabetic medicine : a journal of the British Diabetic Association 20111101
Title: Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
Journal: Clinical therapeutics 20111101
Title: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Journal: Current medical research and opinion 20111101
Title: Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.
Journal: Current drug safety 20111101
Title: Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Journal: Diabetes, obesity & metabolism 20111001
Title: 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.
Journal: Bioorganic & medicinal chemistry 20110915
Title: [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Journal: Orvosi hetilap 20110911
Title: Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Journal: Recent patents on endocrine, metabolic & immune drug discovery 20110901
Title: Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Journal: Current diabetes reviews 20110901
Title: Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901
Title: A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
Journal: Clinical therapeutics 20110801
Title: Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Journal: Drugs 20110730
Title: The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Journal: British journal of clinical pharmacology 20110701
Title: Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Journal: Diabetes, obesity & metabolism 20110701
Title: Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: Postgraduate medicine 20110701
Title: Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Journal: Postgraduate medicine 20110701
Title: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Journal: Clinical therapeutics 20110701
Title: Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
Journal: The Journal of the American Osteopathic Association 20110701
Title: Health economic evaluation of dipeptidyl peptidase-4 inhibitors.
Journal: Indian journal of endocrinology and metabolism 20110701
Title: Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
Journal: The Medical letter on drugs and therapeutics 20110627
Title: Linagliptin approved for type 2 diabetes.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110615
Title: The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Journal: Diabetes, obesity & metabolism 20110601
Title: Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Journal: Expert opinion on investigational drugs 20110601
Title: Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Journal: Advances in therapy 20110601
Title: Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Journal: International journal of clinical pharmacology and therapeutics 20110501
Title: [Incretin therapy and the metabolic syndrome].
Journal: Vnitrni lekarstvi 20110401
Title: Linagliptin: in type 2 diabetes mellitus.
Journal: Drugs 20110326
Title: Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
Journal: Diabetes, obesity & metabolism 20110301
Title: Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers.
Journal: European journal of drug metabolism and pharmacokinetics 20110301
Title: Alogliptin for the treatment of type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998) 20110201
Title: Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Journal: Hospital practice (1995) 20110201
Title: Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
Journal: Drug metabolism and pharmacokinetics 20110101
Title: Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Journal: Diabetes, obesity & metabolism 20110101
Title: Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Journal: Clinical drug investigation 20110101
Title: Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.
Journal: Indian journal of endocrinology and metabolism 20110101
Title: From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.
Journal: Experimental diabetes research 20110101
Title: Vilazodone hydrochloride, linagliptin, and alcaftadine.
Journal: Journal of the American Pharmacists Association : JAPhA 20110101
Title: Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Journal: The open medicinal chemistry journal 20110101
Title: Choosing a gliptin.
Journal: Indian journal of endocrinology and metabolism 20110101
Title: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Journal: PloS one 20110101
Title: Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Journal: Clinical pharmacokinetics 20101201
Title: Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Journal: Diabetic medicine : a journal of the British Diabetic Association 20101201
Title: DPP-4 inhibitors: what may be the clinical differentiators?
Journal: Diabetes research and clinical practice 20101101
Title: Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.
Journal: International journal of clinical pharmacology and therapeutics 20101001
Title: The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100901
Title: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Journal: Clinical pharmacokinetics 20100901
Title: Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
Journal: Journal of clinical pharmacology 20100801
Title: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Journal: Diabetes, obesity & metabolism 20100801
Title: The evolving place of incretin-based therapies in type 2 diabetes.
Journal: Pediatric nephrology (Berlin, Germany) 20100701
Title: Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.
Journal: International journal of clinical pharmacology and therapeutics 20100601
Title: Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Journal: Clinical therapeutics 20100601
Title: Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
Journal: Diabetes, obesity & metabolism 20100501
Title: The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100401
Title: Incretin concepts.
Journal: Diabetes care 20100201
Title: Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Journal: Expert opinion on investigational drugs 20100101
Title: Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Journal: Vascular health and risk management 20100101
Title: Exenatide once weekly: clinical outcomes and patient satisfaction.
Journal: Patient preference and adherence 20100101
Title: New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
Journal: Drug, healthcare and patient safety 20100101
Title: Incorrect description of mode of excretion of linagliptin.
Journal: Drug, healthcare and patient safety 20100101
Title: Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
Journal: Biopharmaceutics & drug disposition 20091101
Title: Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal: Current opinion in investigational drugs (London, England : 2000) 20091001
Title: Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Journal: Diabetes, obesity & metabolism 20090801
Title: Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Journal: Current medical research and opinion 20090801
Title: Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.
Journal: Biopharmaceutics & drug disposition 20090701
Title: Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
Journal: Expert opinion on investigational drugs 20090601
Title: Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models.
Journal: The Journal of pharmacology and experimental therapeutics 20090201
Title: Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
Journal: The Journal of pharmacy and pharmacology 20090101
Title: The centrosome protein NEDD1 as a potential pharmacological target to induce cell cycle arrest.
Journal: Molecular cancer 20090101
Title: Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
Journal: Trials 20090101
Title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers.
Journal: Journal of clinical pharmacology 20081001
Title: 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20080601
Title: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Journal: The Journal of pharmacology and experimental therapeutics 20080401
Title: 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Journal: Journal of medicinal chemistry 20071227
Title: Eckhardt M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d
Title: Thomas L, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action
Title: Schurmann C, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012 Jul;342(1):71-80.
Title: Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7(1):4351.
